Allergan plc
Allergan plc (AGN): 18 pipeline candidates · ~14 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.4 months
D/E 0.52 · 1% dilution
Lead: Approved
18 candidates
N/A
N/A
A transparent, data-derived signal for Allergan plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$999.5M
Quarterly Burn
$831.3M
Runway
14.4 mo
Revenue
$3.6B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| botox | Phase 4 |
| bystolic | Approved |
| cenicriviroc | Phase 3 |
| contigen bard collagen implant | Approved |
| edit-101 | Preclinical |
| formulation a | Phase 2 |
| formulation b | Phase 2 |
| formulation c | Phase 2 |
| gelnique 3% | Approved |
| juvederm injectable gel implants | Approved |
Showing 10 of 18 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Allergan plc's pipeline?
Allergan plc (AGN) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Allergan plc's lead drug candidate?
Allergan plc's most advanced tracked candidate is botox (Phase 4) for Facial Rhytides.
What is Allergan plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Allergan plc has approximately 14.4 months of cash runway.
Get the full picture on Allergan plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.